operative management of patients requiring solid-organ transplantation. Currently, 74% of pediatric heart transplant patients in the United States receive induction therapy, up from 40% in 2002. 1 There are 2 agents currently being used for induction: (i) polyclonal antibody preparations, such as anti-thymocyte or anti-lymphocyte antibodies (ALA), which aim to deplete the majority of T cells; and (ii) monoclonal interleukin-2 receptor antagonists (IL-2RA), which temporarily block activation of T cells without permanently destroying them. 2 ALA are given more frequently than IL-2RA in pediatric heart transplant patients, but both are being used on an increasing basis. 3 A recent review of registry data has demonstrated improved patient survival with use of ALA induction therapy compared with IL-2RA in adult heart transplant patients. 4 There was also improved survival in adult patients with any induction therapy in a cohort with increased risk of mortality after transplantation. 5 Despite these data, the use of induction therapy in the adult population has decreased, with only 50% of patients currently receiving induction therapy, 1 for unclear reasons, but possibly reflecting concerns about adverse impact on infections, tumors and peri-transplant management. The use of any induction therapy in the pediatric heart transplant population has been shown to correlate with a decrease in rejection during the first year after heart transplantation. 6 In addition, a recent study suggested that ALA induction was superior to IL-2RA in pediatric heart transplant patients. 7 Neither of these studies compared specific induction therapy to no induction or stratified patients based on individualized risk.
In this study we sought to determine the impact of induction therapy on post-transplant outcomes. The hypothesis was that induction therapy leads to overall improved patient and graft survival in high-risk patients, with ALA being superior to IL-2RA. Low-risk patients were expected to have similar survival with or without induction therapy and, possibly, benefit from lower rates of infection and posttransplant lymphoproliferative disorder (PTLD) without the use of induction.
Methods
The Pediatric Heart Transplant Study (PHTS) database was used to identify pediatric patients transplanted between January 1, 2001 and December 31, 2013, limiting the inclusion period to the more recent era. All patients were followed as of December 31, 2014 to provide a minimum of 1-year follow-up for all patients. The PHTS is a prospective, event-driven database that collects data from patients at 52 participating pediatric heart transplant centers (see Appendix). Era selected for the study was based on IL-2RA use in the registry. Institutional review board approval is maintained at each participating center.
Induction therapy is defined in the registry as "therapy soon after transplant not used to specifically treat known rejection." Furthermore, it is coded as a "yes" or "no" response, with specific agents listed. Patients were included in the study if they were identified as having received ALA, IL-2RA or no induction therapy (NI). Steroids are not defined as induction therapy in the registry and the use of steroids peri-operatively was not counted as induction. Patients were excluded if they were reported to have received both ALA and IL-2RA, but not if they received additional "other" immunosuppression agents (N ¼ 82 for both induction agents and N ¼ 39 for other induction agents). Other exclusion criteria were survival for o48 hours (n ¼ 15), as there were disproportionate numbers of patients with no induction therapy, which may not reflect the intention to treat with patients dying before induction was initialized. Multi-organ transplants and retransplant patients were also excluded (N ¼ 215).
Patients were then stratified into high-and low-risk groups based on predicted 1-year graft survival, calculated using the previously published multivariable logistic regression model of Schumacher et al. 8 Models are separate for patients with congenital heart disease and cardiomyopathy (C statistic ¼ 0.63 and 0.73, respectively) and incorporate 440 donor and recipient characteristics. Characteristics included in the model equations are race, gender, diagnosis, blood urea nitrogen, panel-reactive antibody, ischemic time, donor age, donor inotropic support and year of transplant ( Figure A1 in Appendix). High-risk (HR) patients were defined as those with the highest predicted 1-year mortality (top 25th percentile). All other patients were standard or low-risk (LR) and represented the lower risk quartiles with predicted 1-year mortality less than the 25th percentile. Mean predicted 1-year mortality was markedly higher in congenital heart disease (CHD) compared with cardiomyopathy (CMP) patients (7.4% for CMP, 24% for CHD; Figure A1 in Appendix). Risk stratification was validated by Kaplan-Meier survival analysis stratified by risk (p o 0.01 for both; Figure A2 in Appendix). This cohort partly overlapped with the training and validation cohorts from the Schumacher et al study, but differed by inclusion of a large proportion of more recent patients and exclusion of earlier patients.
The primary outcome of the study was overall graft survival. Secondary outcomes included incidence of coronary allograft vasculopathy (CAV, defined as abnormal coronary angiography), PTLD throughout the study period, rejection within the first year (defined as rejection by biopsy or other criteria leading to augmented immunotherapy) and infection within the first year (defined as evidence of an infectious process requiring intravenous therapy or a life-threatening infection requiring oral therapy).
Basic demographic information is presented as mean and standard deviation for normally distributed values or median and interquartile range when indicated. Univariate analysis was performed to determine differences in induction group with chisquare test for categorical variables and the independent t-test for continuous variables. Kaplan-Meier analysis was performed for graft survival as well as secondary outcomes, stratified by induction cohort. The log-rank test was used to determine overall and pairwise significant differences. Hazard ratio and multivariable analysis was performed to determine the impact of induction on outcomes and included variables found to be significant on univariate analysis. Early and constant phase hazard is represented separately in the multivariable analysis given the curvilinear relationship of mortality over time. Significance was set at p o 0.05. The analysis was performed using SAS, version 9.4 (SAS Institute, Inc., Cary, NC).
Results

Use of induction therapy
Among the 2,860 study patients who met the criteria, 1,370 (47.9%) received ALA, 707 (24.7%) received IL-2RA and 783 (27.4%) received NI. Overall use of induction therapy has risen in the most recent era, including increased use of both ALA and IL-2RA (60% during 2001 to 2008 vs 86% during 2009 to 2013, p o 0.001; Figure 1a ). In looking at overall use across different age groups, ALA was more commonly used in infant transplants (age o6 months), whereas IL-2RA and NI were more common in patients 5 to 10 years of age and those 410 years of age (p o 0.001; Figure 1b ). During the study, survival improved significantly by era, even after separating the cohort into 3-year periods (p o 0.01; Figure 2 ).
Basic demographic variables are shown in Table 1 . The patients in the ALA group were younger, more likely to have CHD, be listed at highest status (1a or corresponding), have a longer cold ischemic time, and more commonly received additional induction agents (intravenous immunoglobulin [IVIg] or others). Both IL-2RA and NI had higher proportions of CMP and lower urgency status (2 or corresponding) patients.
Survival
In the overall cohort, survival with NI was significantly lower compared with either induction (p o 0.01), whereas ALA and IL-2RA were similar ( Figure 3 ). Using the logrank test, low-risk CMP patients had decreased survival within the first year if they received NI (p o 0.04). Otherwise, after risk stratification by high-and lowmortality groups based on primary diagnosis (CHD or CMP), there were no significant differences in patient survival stratified by induction therapy (Figure 4 ). Five-year estimates for graft survival among high-risk CMP patients with ALA were 76.6%, 74.6% for IL-2RA and 73.2% for NI. For low-risk CMP patients graft survival was 87.3% with ALA, 85.5% with IL-2RA and 83.2% with NI. In the high-risk CHD population, 5-year estimates for graft survival were also similar, showing 68.5% survival with ALA, 57.8% with IL-2RA and 56.3% with NI. In low-risk CHD, graft survival was 78.7% with ALA, 74.7% with IL-2RA and 73.7% with NI.
Secondary outcomes
Analysis of secondary outcomes revealed that overall freedom from rejection within the first year post-transplant was lower with NI in all risk combinations, except for HR CHD (p o 0.05; Figure 5 ). Freedom from rejection was similar for both types of induction therapy. Table 2 shows additional univariate analysis of secondary outcomes. Overall, there was no difference in frequency of outcomes in HR CMP patients, including frequency of rejection, death related to rejection, infection, death related to infection, CAV, primary graft failure or PTLD. In LR CMP patients, increased frequency of rejection within the first year and increased incidence of CAV was seen in patients who received NI compared with either ALA or IL-2R (p o 0.001 for both). Likewise, LR CHD patients had increased frequency of rejection in the first year if they received NI (p ¼ 0.04). Incidence of infection-related complications was lower in CHD and LR CMP patients if they received IL-2RA (p o 0.05; Table 2 ).
Risk factor analysis
Multivariable analysis of factors predicting death in the early phase post-transplant demonstrated no impact of induction therapy on survival for both ALA and IL-2RA when compared with NI. High-risk designation was a risk factor for mortality in both models. In the CMP model, factors associated with increased risk of mortality were ventilator use at transplant and longer donor ischemic time. Factors associated with increased risk of mortality in the Time to graft loss stratified by transplant era.
CHD model included recipient female gender, ventilator use at transplant, earlier year of transplant, and use of other induction agents in combination with ALA or IL-2RA (Table 3) . Multivariable analysis predicting factors for time to first rejection within the first year post-transplant demonstrated that IL-2RA and ALA use was associated with later first rejection in CMP patients. Other factors in this model were older age at transplant, donor ischemic time and earlier transplant era. In the CHD model, factors predicting first rejection panel-reactive antibodies (PRA) 410% were older age at transplant, later transplant era and greater body surface area ( Table 4 ). The model did not show ALA or IL-2RA therapy to be a significant factor in predicting first rejection.
Discussion
The use of induction therapy in a risk-adapted manner or the same protocol for every patient remains highly controversial. Our analysis has attempted to stratify patients using a model including previously identified risk factors to determine whether certain subsets of the pediatric heart transplant population benefit from induction therapy. In the overall cohort, survival was reduced in the NI group compared with either induction strategy; however, this was confounded by improved survival and decreased rejection rates with more recent transplantation and was not sustained as an independent factor in the multivariable analysis for mortality. Although CMP patients were less likely to receive induction therapy, multivariable analysis demonstrated reduced frequency of rejection with either type of induction over NI.
Although broad-based immunosuppressive therapies may be appropriate for patient populations at highest immunologic risk, they may be a disadvantage for lower risk patient populations secondary to adverse effects. These patients may benefit from less aggressive transient immunomodulation (IL-2RA) or no induction. This has been demonstrated in the adult heart transplant population where ALA induction therapy was beneficial in those with 1-year risk of rejection of 45%, but not in those whose risk was o2%. 5 Overall, there was more frequent use of induction therapy in patients having a higher risk of mortality within the first year post-transplant. Surprisingly, although infants have been recognized as generally having a decreased incidence of rejection and a more forgiving immune system, 9 in our cohort these patients were more likely to have received ALA. This may reflect the preferred use of this drug in patients with CHD based on presumed higher risk of early immunologic complications and secondary organ failure. Systematic risk stratification of this patient population is important to balance the risk and benefits of these treatments adequately and to identify those who would benefit most from induction therapy.
Recent retrospective studies using data from the United Network for Organ Sharing/Organ Procurement and Transplant Network (UNOS/OPTN) indicated improved survival with ALA induction therapy. Ansari and colleagues found that survival was better in patients who received ALA vs IL-2RA in adult heart transplants, with separation of the cohorts occurring late post-transplant, beyond 2 years. 4
Figure 3
Graft survival after transplant by induction therapy. ALA, anti-lymphocyte antibodies; IL2RA, interleukin-2 receptor antagonist.
Figure 4
Graft survival by induction therapy stratified by diagnosis and risk for 1-year mortality. HD, heart disease; ALA, antilymphocyte antibodies; IL2RA, interleukin-2 receptor antagonist.
This finding was also seen in a pediatric cohort of patients in UNOS, where the use of ALA was associated with improved survival on multivariable analysis. 7 Although the cohort studied in that analysis was similar to that in the current study, the impact of year of transplant was not included in the multivariable analysis, which may explain the different findings. A more recent study by Butts and colleagues demonstrated the survival benefit of using ALA in those sensitized (PRA 450%) and those with congenital heart disease in a propensity match comparison. 10 The data from all of those studies originated exclusively from centers in the United States, which predominantly use ALA, and the difference in survival was only detected at 5 and 10 years, representing very small numbers and potentially a highly selected cohort for the IL-2RA group.
The theoretical advantage of ALA vs IL-2RA has been greater protection against rejection. Flaman and colleagues found that there was a lower rejection rate in patients who received ALA than in those who received IL-2RA in a population of adult heart transplant recipients. Meanwhile, other studies showed that use of IL-2RA is not inferior to ALA in the prevention of rejection. [11] [12] [13] [14] No prospective trial has been conducted comparing induction agents in the pediatric heart transplant population; however, induction therapy of any kind was found to be protective for rejection in registry studies. 6, 15 Benefits were found with regard to rejection and infection in the first year when looking at the populations individually.
A potential drawback of the routine use of ALA in the heart transplant population is the increased risk of infections. 16 Mattei and colleagues demonstrated that IL-2RA induction resulted in decreased rates of infection compared with ALA in adult heart transplant patients. 17 Boucek and colleagues did not find an increased risk of infection in the pediatric population, back in an era before the use of IL-2RA. 18 Gajarski and colleagues reached the same conclusion in a more contemporary cohort of pediatric patients, but only a small group of patients in their study had received IL-2RA, limiting the ability to compare outcomes. 19 Overall, the frequency of infections was lowest in those patients who received IL-2RA, with similar rates for ALA and NI, with the exception of high-risk CMP patients in whom the rate of infection was similar among all therapy groups. The increased risk of infections in the NI group may be reflective of immunosuppression augmentation for rejection, which was more common in this population. Given that, in our study, the low-risk CMP patients showed a similar benefit from both a graft survival and rejection standpoint as those who received ALA, IL-2RA may offer the best risk-to-benefit ratio in this patient population.
Figure 5
Time to first rejection by induction therapy stratified by diagnosis and risk for 1-year mortality. ALA, anti-lymphocyte antibodies; IL2RA, interleukin-2 receptor antagonist. CAV and PTLD are other significant post-transplant morbidities that should be considered when analyzing the benefits of induction therapy. Reduced CAV after induction was not seen in our analysis, except in lowrisk CMP patients, which may be the result of the decreased rates of early rejection among these patients. Adult studies have identified reduced intravascular ultrasound (IVUS) changes within the first year post-transplant in patients who received ALA or IL-2RA compared with those who received NI; however, IVUS data are only available for 2% of the CMP and 5.3% of the CHD patients, most likely due to the technical limitations of applicability in the pediatric population. 20, 21 Likewise, the incidence of PTLD was not higher in patients receiving either induction therapy. This dispels one of the major concerns about the general use of ALA in children and is in concordance with findings from other studies that did not show a correlation between induction and the risk of PTLD. 16, 19, 22, 23 One significant limitation of our analysis was the impact of improving patient survival during the study. This limitation persisted, despite evaluating only patients transplanted after 2001. This has been described in other studies and is most likely multifactorial with multiple shifts in clinical practice, including decreased use of extracorporeal membrane oxygenation (ECMO), increased use of durable mechanical support, improved peri-transplant management, advancements in the assessment of pre-formed human leukocyte antigen (HLA) antibodies, and optimized screening and prophylaxis for infectious diseases. On multivariable analysis, accounting for year of transplant, use of either ALA or IL-2RA was not found to be significantly associated with improved survival. Although the model attempted to account for the influence of year of transplant on survival, elimination of the confounding variables, as in a randomized, controlled trial, would be superior.
Other limitations of this analysis include factors consistent with other studies using large registry databases. On review of induction therapy by center, there were clear preferences for induction therapy use among centers that were difficult to adjust in the analysis. Clinical decisionmaking for choosing agents was not captured and is unknown. A preference for a more aggressive approach to early immunosuppression can be seen in the demographics of patients receiving ALA, indicating that this was preferentially used in patients with CHD and those with a higher risk profile. It is also possible that the 82 patients excluded for receiving both types of induction represent a particularly high-risk population receiving escalating intensity induction. Interestingly, our analysis demonstrated a disadvantage with NI in low-risk patients, which questions the rationale for a less aggressive induction strategy in this population.
Although appropriate patient selection for induction therapy appears promising in the adult population, both CHD and CMP patients at low risk for 1-year mortality had increased rejection if they received NI. Low-risk CMP patients, in particular, had worse survival and increased frequency of both rejection and CAV with NI. This occurred with no increased risk of infection in this patient population, with the lowest frequency of infection for IL-2RA among all low-risk patients.
In a large population of pediatric heart transplant patients, post-transplant survival, as well as use of induction therapy, has been increasing. Use of either induction therapy resulted in delayed occurrence of first rejection in LR CHD and CM patients, with no increased risk of PTLD or infection. Especially in the LR CMP population, induction with IL-2RA appears to generate a beneficial profile with regard to reducing mortality, early rejection and infection. Although overall graft survival was lower in those patients who received NI, a clear relationship between induction therapy and survival could not be proven in this study based on multivariable analysis. A prospective, controlled trial comparing a risk-adapted induction model and no induction will be necessary to determine the effect of induction on improved graft survival in this patient population. A multicenter collaboration following strict protocols will be the only way to determine optimal management of these patients.
Disclosure statement
None of the authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose. This investigation was funded by the Pediatric Heart Transplant Study.
